Abstracts tagged "osteoporosis"

Abstract Number: 1312 • ACR Convergence 2022
Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Leny Pearman⁴, jake Mathew⁴, Yamei Wang⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedar-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Waltham, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Previous cost-effectiveness analyses in postmenopausal women (PmW) with osteoporosis (OP) demonstrated that sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) resulted in lower…
Abstract Number: 1338 • ACR Convergence 2022
Patients’ Perspectives and Experiences of Medication Use in Osteoporosis – a Qualitative Systematic Review and Thematic Synthesis
Sagarika Dey¹, Gloria Spratt², Muguet Koobasi³, Carol Vleeskens⁴, Carlos El-Haddad⁵ and Ayano Kelly⁶, ¹School of Clinical Medicine, South Western Sydney Campus, University of New South Wales, Parramatta, New South Wales, Australia, ²Physiotherapy Department and Rheumatology Department, Liverpool Hospital; Zone34 Sports Physiotherapy, Liverpool, Australia, ³Knowledge Centre for Health Ghent, Ghent University, Ghent, Belgium, ⁴Sydney Partnership for Health Medical Research and Enterprise Consumer Community Council, Liverpool, Australia, ⁵Rheumatology Department, Liverpool Hospital, Liverpool, Australia, ⁶South Western Sydney Campus, UNSW Medicine & Health, Braddon, Australia
Background/Purpose: Suboptimal adherence to anti-osteoporotic medications presents a growing social and economic concern. Yet, it is unclear what patients' perspectives and experiences are regarding medication…
Abstract Number: 0575 • ACR Convergence 2022
Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment with Denosumab or Zoledronic Acid for Osteoporosis
Leslie Spangler¹, Carrie Nielson¹, M Alan Brookhart², Rohini K Hernandez¹, Robert Kees Stad³ and Jay Lin¹, ¹Amgen, Inc., Thousand Oaks, CA, ²NoviSci, Inc., Durham, NC, ³Amgen Inc., Zug, Switzerland
Background/Purpose: There has been inconsistent evidence published regarding the cardio- and cerebrovascular benefits and risks of anti-osteoporosis medications. EU regulators requested Amgen to evaluate the…
Abstract Number: 1313 • ACR Convergence 2022
The Role of Tryptophan and Its Metabolites in Risk for Incident Hip Fractures and Frailty: The Cardiovascular Health Study
Laura Carbone¹, Petra Bůžková², John Robbins³, Howard Fink⁴, Joshua Barzilay⁵, Rachel Elam¹ and Carlos Isales¹, ¹Augusta University, Augusta, GA, ²University of Washington, Seattle, WA, ³UC Davis, Davis, CA, ⁴University of Minnesota, Minneapolis, MN, ⁵Kaiser Permanente, Atlanta, GA
Background/Purpose: Essential amino acids including tryptophan (trp) are building blocks for protein, and adequate protein intake is important for skeletal homeostasis. In experimental studies, trp…
Abstract Number: 1477 • ACR Convergence 2022
Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Hospital Authority, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence and risk factors of fragility fractures in a longitudinal cohort of patients with SLE.Methods: All patients who fulfilled ≥4 1997…
Abstract Number: 0576 • ACR Convergence 2022
Comparative Effectiveness of Osteoporosis (OP) Therapies Among a Population of Postmenopausal (PM) Women in the United States (U.S.)
Min Kim¹, Leah J McGrath², David Pritchard², Peter Samai², Jay Lin¹, Robert Kees Stad³, Leslie Spangler¹, Michele McDermott¹, Brian D Bradbury⁴ and M Alan Brookhart², ¹Amgen, Inc., Thousand Oaks, CA, ²NoviSci, Inc., Durham, NC, ³Amgen Inc., Zug, Switzerland, ⁴Amgen Inc., 1 Amgen Center Drive
Background/Purpose: Although clinical trials evaluating the efficacy of osteoporosis (OP) therapies have shown that denosumab (Dmab) significantly increases bone mineral density at pivotal sites compared…
Abstract Number: 1314 • ACR Convergence 2022
Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
Ruban Dhaliwal¹, David Kendler², Kenneth Saag³, Steven Ing⁴, Andrea Singer⁵, Robert Adler⁶, Leny Pearman⁷, Yamei Wang⁷ and Bruce Mitlak⁸, ¹SUNY Upstate Medical University, Syracuse, NY, ²University of British Columbia, Vancouver, BC, Canada, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Ohio State University Wexner Medical Center, Colombus, OH, ⁵MedStar Georgetown University Hospital, Washington, DC, ⁶Hunter Holmes McGuire Veterans Affairs Medical Center-Richmond, Richmond, VA, ⁷Radius Health, Inc., Waltham, MA, ⁸Radius Health, Inc, Boston, MA
Background/Purpose: In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) study, 12 months of abaloparatide therapy resulted in rapid and significant improvements in…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
Abstract Number: 1135 • ACR Convergence 2021
Osteoporosis Assessment and Outcomes in Candidates for Liver Transplantation in a Tertiary Center
Cristina Rodríguez-Alvear¹, MARIANO ANDRES¹, Maria-Luisa Peral-Garrido², Irene Calabuig³, Ernesto Tovar-Sugrañes¹, Mari-Carmen López-González¹, Pilar Bernabeu¹, Agustín Martínez-Sanchis¹, Ximo Esteve¹, Paloma Vela¹, Cayetano Miralles¹ and Maria Vega Jovani Casano⁴, ¹Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Novelda, Spain, ³Hospital General Universitario de Alicante, Alicante, Spain, ⁴National Health system, Alicante, Spain
Background/Purpose: A rapid loss of bone mass and an increase in fractures have been described in the first six months after liver transplantation. This phenomenon…
Abstract Number: 1137 • ACR Convergence 2021
REMS Technology for the Assessment of Bone Health in a Male Population
Delia Ciardo¹, Paola Pisani¹, Fiorella Anna Lombardi¹, Marco Di Paola¹, Roberto Franchini¹, Maurizio Muratore², Francesco Conversano¹ and Sergio Casciaro¹, ¹National Research Council, Institute of Clinical Physiology, Lecce, Italy, Lecce, Italy, ²Vito Fazzi Hospital, ASL-LE, O.U. of Rheumatology, Lecce, Italy, Lecce, Italy
Background/Purpose: This study aimed to evaluate the diagnostic accuracy of the ultrasound-based densitometric technology called Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis…
Abstract Number: 1138 • ACR Convergence 2021
Assessing Trends in Dual Energy X-Ray Absorptiometry (DXA) Utilization Among Medical Providers in the United States
Timothy Edgil¹, Kenneth Saag², Jeffrey Curtis³ and Maria I. Danila², ¹Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The twenty first century has seen falling reimbursement rates for dual energy X-ray absorptiometry (DXA) testing coupled with a rising elderly population in the…
Abstract Number: 1139 • ACR Convergence 2021
Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Muntarin Karim¹, lorien ahn², Jordan Thompson¹, Christina Downey³, Lorena Salto⁴ and Karina Torralba⁵, ¹Loma Linda University, Redlands, CA, ²loma linda university medical center, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University Health, Loma Linda, CA, ⁵Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA
Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
Abstract Number: 1140 • ACR Convergence 2021
Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?
Alexandra Chop¹, Rajesh Kupuraju¹, Ruchi Patel¹, Kristen Salava¹, Madhuri Duggirala¹, Aparna Baburaj¹, Andrea Berger², Jason Brown¹ and David Bulbin³, ¹Geisinger Medical Center, Danville, PA, ²Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: Glucocorticoids are commonly prescribed for a multitude of indications, yet have many side effects, one of which is glucocorticoid induced osteoporosis (GIOP). The 2017…
Abstract Number: 1141 • ACR Convergence 2021
Factors Associated with Fragility Fracture in Patients with Systemic Mastocytosis: Data from an Inception Cohort in a Single Centre
Karen Carpio Astudillo¹, Filip Skrabski², ISABEL CASTREJON³, Jose Maria Alvaro-Gracia², Alicia Garcia Prieto² and Teresa González⁴, ¹Hospital General Universitario Gregorio Maraon, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pfizer Spain, Chicago, ⁴H Gregorio Maraon, Madrid, Spain
Background/Purpose: Systemic Mastocytosis (SM) is a very rare disease (0,5 -1 per 10000 in adults). Most common manifestations are skin related or anaphylaxis, however almost…
Abstract Number: 1143 • ACR Convergence 2021
Predictors of Engagement in Bone Health Care Among Rural Veterans at Risk for Osteoporosis
Karla Miller¹, Kimberly McCoy², Christopher Richards², Aaron Seaman³ and Samantha Solimeo⁴, ¹Department of Internal Medicine, Rheumatology Section, Veterans Affairs Salt Lake City Health Care System; Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ²VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation, Department of Veterans Affairs, CADRE, Iowa City VA HCS, Iowa City, IA, ³VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City (VRHRC-IC); Division of Genera l Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, ⁴VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation; and Primary Care Analytics Team Iowa City (PCAT-IC), Department of Veterans Affairs, CADRE, Iowa City VA HCS Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: A virtual bone health team (BHT) model was implemented to identify, screen, and treat rural Veterans at risk for osteoporosis. This study was conducted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].